Form 4: Inovio Pharmaceuticals Director Jay Shepard Reports Stock Unit Vesting

Director Jay Shepard reports vesting of restricted stock units convertible to common stock in Inovio Pharmaceuticals.

Summary

• On May 15, 2024, Jay Shepard, a director of Inovio Pharmaceuticals, had 2,166 restricted stock units vest.
• These units converted into 2,166 shares of common stock.
• The reported transaction reflects the vesting of these units, which were previously granted as a contingent right to receive common stock.
• The filing also gives effect to a 1-for-12 reverse stock split that Inovio Pharmaceuticals implemented on January 24, 2024.
• Following the transaction, Shepard directly owns 7,042 shares of Inovio Pharmaceuticals.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to stock unit vesting, which is neither particularly positive nor negative.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, such as directors and officers. This allows investors to monitor the actions of those with the most knowledge of the company.

Stakeholder Impact

• The vesting of stock units could have a minor dilutive effect on existing shareholders.

Key Dates